Evidence map›Paper›PMID 42559085›Full record

ArticleEJHaem2026

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Jacob M Rowe, Yishai Ofran

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05599360 (Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05599360 phase2active not recruitingnot on this map

Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study

TypeinterventionalSponsorShaare Zedek Medical CenterRan2022 to 2028Enrolled20ConditionsLeukemia, Myeloid, AcuteArmsVyxeos, Mylotarg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chezi GanzelThe Hematology and Bone Marrow Transplantation Department The Eisenberg Research and Development Authority Shaare Zedek Medical Center The Hebrew University of Jerusalem Jerusalem Israel.
Avraham FrischDepartment of Hematology and Bone Marrow Transplantation Rambam Health Care Campus Haifa Israel.
Ofir WolachInstitute of Hematology Davidoff Cancer Center Rabin Medical Center-Beilinson Hospital Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel.
Yakir MosheBone Marrow Transplantation Unit Department of Hematology Tel Aviv Sourasky Medical Center Tel Aviv Israel.
Baher KrayemDepartment of Hematology and Bone Marrow Transplantation Rambam Health Care Campus Haifa Israel.
Neta DorDepartment of Hematology Shaare Zedek Medical Center Jerusalem Israel.
Jacob M RoweDepartment of Hematology and Bone Marrow Transplantation Rambam Health Care Campus Haifa Israel.
Yishai OfranThe Hematology and Bone Marrow Transplantation Department The Eisenberg Research and Development Authority Shaare Zedek Medical Center The Hebrew University of Jerusalem Jerusalem Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CPX-351 is associated with reduced non-hematologic toxicity, but its cardiac safety is not well defined. We prospectively assessed ejection fraction (EF) and global longitudinal strain (GLS) in younger adults with AML treated with a single CPX-351-based induction. Median changes were mild and comparable to standard "7 + 3". However, 27% developed clinically significant cardiac changes. These findings support prospective cardiac monitoring and the need for comparative studies. Trial Registration: NCT05599360.

Indexed as

AMLanthracyclinescardiotoxicityCPX‐351ejection fractionglobal longitudinal strainVyxeos

Identifiers

PMID42559085
PMCPMC13439510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.